SHINCORT INJECTION 10 mgml

Pays: Singapour

Langue: anglais

Source: HSA (Health Sciences Authority)

Ingrédients actifs:

TRIAMCINOLONE ACETONIDE

Disponible depuis:

YUNG SHIN PHARMACEUTICAL (SINGAPORE) PTE LTD

Code ATC:

H02AB08

Dosage:

10 mg/ml

forme pharmaceutique:

INJECTION

Composition:

TRIAMCINOLONE ACETONIDE 10 mg/ml

Mode d'administration:

INTRAMUSCULAR, INTRADERMAL

Type d'ordonnance:

Prescription Only

Fabriqué par:

YUNG SHIN PHARMACEUTICAL IND CO LTD

Statut de autorisation:

ACTIVE

Date de l'autorisation:

1991-12-03

Résumé des caractéristiques du produit

Shincort Injection provides a synthetic corticosteroid, structurally
related to dexamethasone, with
marked anti-inflammatory action. It is primarily glucocorticoid in
properties, possessing minimal
sodium and water retention when used in therapeutic dosage.
INGREDIENT:
Each mL of sterile aqueous suspension contains:
Triamcinolone Acetonide
........................................................................................................
10mg
ACTIONS:
Naturally ocurring glucocorticoids, which also have salt-retaining
properties, are used as replacement
therapy in adrenocortical deficiency states. Their synthetic analogs
are primarily used for their
potent anti-inflammatory effects in disorders of many organ systems.
Glucocorticoids cause profound and varied metabolic effects. In
addition, they modify the body's
immune responses to diverse stimuli.
INDICATIONS:
Rheumatic disorders: rheumatoid arthritis, osteoarthritis, synovitis.
Allergic states: bronchial asthma, allergic rhinitis, allergic
dermatitis.
Collagen diseases. Dermatologic diseases. Severe acute and chronic
allergic and inflammatory
opthalmic diseases.
DOSAGE AND ADMINISTRATION:
Intramuscular administration.
For adults and children over 12 years of age, the suggested initial
dose is 60 mg, injected deeply
into the gluteal muscle. Dosage is usually adjusted within the range
of 40 mg to 80 mg.
For children from 6 to 12 years of age, the suggested initial dose is
40 mg, although dosage
depends more on the severity of symptoms than on age or weight.
For intra-articular or intrabursal administration and for injection
into tendon sheaths may vary
from 2.5 mg to 5 mg for smaller joints, and from 5 mg to 15 mg for
larger joints depending on
the specific disease entity being treated. Single injections into
several joints for multiple locus
involvement, up to a total of 20 mg or more, have been given without
incident.
For intradermal administration, the initial dose of triamcinolone
acetonide will vary depending
upon the specific disease entity being treate